Call for entries to Rainer Rudolph Foundation prizes

Closing date is 31 March

Young researchers who have completed an outstanding final thesis in the fields of protein biochemistry and biotechnology have another month to apply for a €1,000 Rainer Rudolph Foundation prize. Applications should be submitted to the Foundation in Germany by 31 March.

Friends, companions, former colleagues and staff of the late Professor Dr Rainer Rudolph established The Rainer Rudolph Foundation in 2011 to honour his scientific work. Prior to his death in 2009, Professor Rudolph was among the world’s leading protein biochemists as well as the co-founder of Scil Proteins, the company which now sponsors The Rainer Rudolph Foundation.


Dr Ulrike Fiedler, chief executive of the Foundation and Scil Proteins, said: ‘During his work, Professor Rudolph placed particular emphasis on linking scientific research with industrial applications and consequently, the foundation of Scil Proteins was a logical step for him. Through the years, we came to know and appreciate Professor Rudolph as a highly respected scientist and competent industrial partner. The Rainer Rudolph prizes have been established to encourage upcoming generations of scientists to excel in their work and therefore, I hope many young researchers in the fields of protein biochemistry and biotechnology will apply.’

You may also like

Manufacturing

Wacker acquires Scil Proteins Production

The transaction will create a leading microbial-based biopharmaceutical manufacturer
Ingredients

Scil Proteins receives EMA approval for commercial production of Reteplase

The recombinant protein will be produced in Halle, Germany
Research & Development

Scil Proteins signs partnership to research cancer therapies

Will work with Martin Luther University Halle-Wittenberg
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Pharmaceutical

New research suggests repurposed diabetic drug may help prostate cancer

A class of medication called SGLT2 inhibitors, traditionally used for diabetes, may help slow prostate cancer progression in men receiving hormone treatment
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Subscribe now